



Atty Dkt. No.: UCAL217
USSN: 10/033,526

administering an inhibitor; and

Group VII: Claims 25, 27, and 29-30, drawn to a pharmaceutical compositions and kits comprising the same.

Applicants hereby elect to prosecute the claims of Group I (claim 1-6, 23-24, 28, and 31), with traverse.

2) Peptides

Species A: SEQ ID NO:01

Species B: SEQ ID NO:02

Species C: SEQ ID NO:03

Species D: SEQ ID NO:04

Applicants hereby elect SEQ ID NO:1, with traverse.

The above elections are made with traverse. As stated in the MPEP §803, if search and examination of an entire application can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to independent or distinct inventions. It is Applicants' position that it would not be unduly burdensome to perform a search on claims 1-31, and on SEQ ID NO:01-04, together. Accordingly, Applicants traverse the restriction requirement.

Applicants expressly reserve the right under 35 USC §121 to file one or more divisional applications directed to the non-elected subject matter during the pendency of this application.

SPECIES ELECTION

The Office Action further set forth an election of species requirements, as follows:

The Office Action stated that **if Group I claims are elected**, then one of the following species must be elected:

- a) Alzheimer's disease
- b) coronary artery disease
- c) head trauma
- d) stroke

Applicants hereby elect the species of "Alzheimer's disease." Of the elected Group I claims, the claims readable on the elected species are claims 1-6, 23, 24, 28, and 31. The Office Action stated that claim 4 is generic.



Atty Dkt. No.: UCAL217
USSN: 10/033,526

Applicants expressly reserve the right under 35 USC §121 to file one or more divisional applications directed to the non-elected species during the pendency of this application.


With respect to election of species, Applicants respectfully request rejoinder of withdrawn species claims upon allowance of a claim that encompasses the currently withdrawn species.

II. CONCLUSION

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number UCAL217.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: Nov. 8, 2002

By: 
Paula A. Borden
Registration.No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231